Cell Reports Medicine · 2024 · 18 citations · 32 references
Life SciencesMolecular BiologyOncologyCancer PharmacologyGene ExpressionMolecular OncologyCancer Cell SignalingCyclin-dependent KinasesDna Damage SignalingProstate CancerSynthetic LethalitySynthetic Lethality In CancerCdk InhibitorsDna Damage Response PathwaysGene-length Dependent ElongationGenomic Stability MaintenancePhosphatidylinositol 3-Kinase-akt PathwayPi3k-akt Signaling PathwayTranscription Elongation ControlTranscriptional Elongation Control
Cyclin-dependent kinases 12/13 play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability. Biallelic CDK12 loss has been documented in various malignancies. Here, we develop a selective CDK12/13 PROTAC degrader, YJ9069, which effectively inhibits proliferation in subsets of prostate cancer cells preferentially over benign immortalized cells. CDK12/13 degradation rapidly triggers gene-length-dependent transcriptional elongation defects, leading to DNA damage and cell-cycle arrest. In vivo , YJ9069 significantly suppresses prostate tumor growth. Modifications of YJ9069 yielded an orally bioavailable CDK12/13 degrader, YJ1206, which exhibits comparable efficacy with significantly less toxicity. To identify pathways synthetically lethal upon CDK12/13 degradation, phosphorylation pathway arrays were performed using cell lines treated with YJ1206. Interestingly, degradation or genetic knockdown of CDK12/13 led to activation of the AKT pathway. Targeting CDK12/13 for degradation, in conjunction with inhibiting the AKT pathway, resulted in a synthetic lethal effect in preclinical prostate cancer models. • Development of an orally bioavailable CDK12/13 degrader (YJ1206) • YJ1206 exhibits minimal adverse effects in immune-competent mice • YJ1206 is efficacious in preclinical models of advanced prostate cancer • YJ1206 induces synthetic lethality in conjunction with AKT pathway inhibition Chang et al. develop YJ1206, an orally bioavailable degrader that exhibits high specificity in degrading CDK12/13 and demonstrates robust anti-tumor activity in vivo . The degradation of CDK12/13 leads to activation of the AKT pathway. YJ1206 in combination with AKT inhibitors achieves a striking synthetic lethal effect in prostate cancer models.
32
Rebecca L. Siegel, Angela N. Giaquinto, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2024 · 9K citations · Full text
Medicine, Oncology, Cancer Control +16
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan R. Robinson, Eliezer M. Van Allen, Yi-Mi Wu et al. · Cell · 2015 · 3.6K citations · Full text
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso, Yi-Mi Wu, Dan R. Robinson et al. · Nature · 2012 · 2.6K citations
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
Chris Tran, Samedy Ouk, Nicola J. Clegg et al. · Science · 2009 · 2.3K citations · Full text
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations
Pharmacy, Oncology, Pharmacotherapy +17